# Romiplostim N01 for the Treatment of Thrombocytopenia Associated With Radiotherapy-Combined Treatment Regimens in Patients With Solid Tumors

> **NCT07128576** · PHASE2 · NOT_YET_RECRUITING · sponsor: **Zhujiang Hospital** · enrollment: 60 (estimated)

## Conditions studied

- Solid Tumors

## Interventions

- **DRUG:** Romiplostim N01

## Key facts

- **NCT ID:** NCT07128576
- **Lead sponsor:** Zhujiang Hospital
- **Sponsor class:** OTHER
- **Phase:** PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** NOT_YET_RECRUITING
- **Start date:** 2025-09-15
- **Primary completion:** 2027-08-15
- **Final completion:** 2028-12-31
- **Target enrollment:** 60 (ESTIMATED)
- **Last updated:** 2025-09-04


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT07128576

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT07128576, "Romiplostim N01 for the Treatment of Thrombocytopenia Associated With Radiotherapy-Combined Treatment Regimens in Patients With Solid Tumors". Retrieved via AI Analytics 2026-06-08 from https://api.ai-analytics.org/clinical/NCT07128576. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*